Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.560
-0.090 (-5.45%)
At close: Nov 20, 2024, 4:00 PM
1.600
+0.040 (2.56%)
Pre-market: Nov 21, 2024, 7:00 AM EST
Cardiol Therapeutics Employees
Cardiol Therapeutics had 6 employees as of December 31, 2018.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,458,098
Market Cap
124.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2018 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 185 |
| Pro-Dex | 148 |
| Seer, Inc. | 147 |
| Vaxart | 109 |
| PepGen | 64 |
| Black Diamond Therapeutics | 54 |
| Elutia | 54 |
| Acumen Pharmaceuticals | 52 |
CRDL News
- 2 days ago - Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp
- 8 days ago - Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - GlobeNewsWire
- 4 weeks ago - Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile Corp
- 5 weeks ago - Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Newsfile Corp